FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108991533> ?p ?o ?g. }

• W2108991533 abstract "Background Chronic anticoagulation with vitamin K antagonists (VKAs) prevents ischaemic stroke and systemic embolism in people with non‐valvular atrial fibrillation (AF) but dose adjustment, coagulation monitoring and bleeding limits its use. Direct thrombin inhibitors (DTIs) are under investigation as potential alternatives. Objectives To assess (1) the comparative efficacy of long‐term anticoagulation using DTIs versus VKAs on vascular deaths and ischaemic events in people with non‐valvular AF, and (2) the comparative safety of chronic anticoagulation using DTIs versus VKAs on (a) fatal and non‐fatal major bleeding events including haemorrhagic strokes, (b) adverse events other than bleeding and ischaemic events that lead to treatment discontinuation and (c) all‐cause mortality in people with non‐valvular AF. Search methods We searched the Cochrane Stroke Group Trials Register (July 2013), the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, May 2013), MEDLINE (1950 to July 2013), EMBASE (1980 to October 2013), LILACS (1982 to October 2013) and trials registers (September 2013). We also searched the websites of clinical trials and pharmaceutical companies and handsearched the reference lists of articles and conference proceedings. Selection criteria Randomised controlled trials (RCTs) comparing DTIs versus VKAs for prevention of stroke and systemic embolism in people with non‐valvular AF. Data collection and analysis All three review authors independently performed data extraction and assessment of risk of bias. Primary analyses compared all DTIs combined versus warfarin. We performed post hoc analyses excluding ximelagatran because this drug was withdrawn from the market owing to safety concerns. Main results We included eight studies involving a total of 27,557 participants with non‐valvular AF and one or more risk factors for stroke; 26,601 of them were assigned to standard doses groups and included in the primary analysis. The DTIs: dabigatran 110 mg twice daily and 150 mg twice daily (three studies, 12,355 participants), AZD0837 300 mg once per day (two studies, 233 participants) and ximelagatran 36 mg twice per day (three studies, 3726 participants) were compared with the VKA warfarin (10,287 participants). Overall risk of bias and statistical heterogeneity of the studies included were low. The odds of vascular death and ischaemic events were not significantly different between all DTIs and warfarin (odds ratio (OR) 0.94, 95% confidence interval (CI) 0.85 to 1.05). Sensitivity analysis by dose of dabigatran on reduction in ischaemic events and vascular mortality indicated that dabigatran 150 mg twice daily was superior to warfarin although the effect estimate was of borderline statistical significance (OR 0.86, 95% CI 0.75 to 0.99). Sensitivity analyses by other factors did not alter the results. Fatal and non‐fatal major bleeding events, including haemorrhagic strokes, were less frequent with the DTIs (OR 0.87, 95% CI 0.78 to 0.97). Adverse events that led to discontinuation of treatment were significantly more frequent with the DTIs (OR 2.18, 95% CI 1.82 to 2.61). All‐cause mortality was similar between DTIs and warfarin (OR 0.91, 95% CI 0.83 to 1.01). Authors' conclusions DTIs were as efficacious as VKAs for the composite outcome of vascular death and ischaemic events and only the dose of dabigatran 150 mg twice daily was found to be superior to warfarin. DTIs were associated with fewer major haemorrhagic events, including haemorrhagic strokes. Adverse events that led to discontinuation of treatment occurred more frequently with the DTIs. We detected no difference in death from all causes." @default.
• W2108991533 created "2016-06-24" @default.
• W2108991533 creator A5006641050 @default.
• W2108991533 creator A5047512689 @default.
• W2108991533 creator A5086352979 @default.
• W2108991533 date "2014-03-27" @default.
• W2108991533 modified "2023-10-04" @default.
• W2108991533 title "Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation" @default.
• W2108991533 cites W123089759 @default.
• W2108991533 cites W1567051068 @default.
• W2108991533 cites W1738640266 @default.
• W2108991533 cites W1804375307 @default.
• W2108991533 cites W1860620208 @default.
• W2108991533 cites W1967889750 @default.
• W2108991533 cites W1978506115 @default.
• W2108991533 cites W1982179895 @default.
• W2108991533 cites W1985638561 @default.
• W2108991533 cites W1992048048 @default.
• W2108991533 cites W1997637512 @default.
• W2108991533 cites W1999468381 @default.
• W2108991533 cites W2000438765 @default.
• W2108991533 cites W2016875529 @default.
• W2108991533 cites W2019561783 @default.
• W2108991533 cites W2020148377 @default.
• W2108991533 cites W2031717872 @default.
• W2108991533 cites W2044180326 @default.
• W2108991533 cites W2051910688 @default.
• W2108991533 cites W2061447560 @default.
• W2108991533 cites W2064696767 @default.
• W2108991533 cites W2075352627 @default.
• W2108991533 cites W2079420595 @default.
• W2108991533 cites W2082755584 @default.
• W2108991533 cites W2097624562 @default.
• W2108991533 cites W2097854437 @default.
• W2108991533 cites W2098837786 @default.
• W2108991533 cites W2101669068 @default.
• W2108991533 cites W2106981695 @default.
• W2108991533 cites W2108991533 @default.
• W2108991533 cites W2110145942 @default.
• W2108991533 cites W2112378432 @default.
• W2108991533 cites W2113021651 @default.
• W2108991533 cites W2115348966 @default.
• W2108991533 cites W2116489124 @default.
• W2108991533 cites W2118092611 @default.
• W2108991533 cites W2119808478 @default.
• W2108991533 cites W2121366426 @default.
• W2108991533 cites W2125435699 @default.
• W2108991533 cites W2136065216 @default.
• W2108991533 cites W2136489990 @default.
• W2108991533 cites W2143034000 @default.
• W2108991533 cites W2143926385 @default.
• W2108991533 cites W2146324319 @default.
• W2108991533 cites W2151074096 @default.
• W2108991533 cites W2152243754 @default.
• W2108991533 cites W2153326621 @default.
• W2108991533 cites W2154464108 @default.
• W2108991533 cites W2159193915 @default.
• W2108991533 cites W2161876144 @default.
• W2108991533 cites W2162508946 @default.
• W2108991533 cites W2166503147 @default.
• W2108991533 cites W2168557505 @default.
• W2108991533 cites W2169233115 @default.
• W2108991533 cites W2172245650 @default.
• W2108991533 cites W2238152425 @default.
• W2108991533 cites W2339494584 @default.
• W2108991533 cites W2403689317 @default.
• W2108991533 cites W4231148263 @default.
• W2108991533 cites W4233664165 @default.
• W2108991533 cites W4292280632 @default.
• W2108991533 doi "https://doi.org/10.1002/14651858.cd009893.pub2" @default.
• W2108991533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24677203" @default.
• W2108991533 hasPublicationYear "2014" @default.
• W2108991533 type Work @default.
• W2108991533 sameAs 2108991533 @default.
• W2108991533 citedByCount "38" @default.
• W2108991533 countsByYear W21089915332014 @default.
• W2108991533 countsByYear W21089915332015 @default.
• W2108991533 countsByYear W21089915332016 @default.
• W2108991533 countsByYear W21089915332017 @default.
• W2108991533 countsByYear W21089915332018 @default.
• W2108991533 countsByYear W21089915332019 @default.
• W2108991533 countsByYear W21089915332020 @default.
• W2108991533 countsByYear W21089915332021 @default.
• W2108991533 countsByYear W21089915332022 @default.
• W2108991533 countsByYear W21089915332023 @default.
• W2108991533 crossrefType "journal-article" @default.
• W2108991533 hasAuthorship W2108991533A5006641050 @default.
• W2108991533 hasAuthorship W2108991533A5047512689 @default.
• W2108991533 hasAuthorship W2108991533A5086352979 @default.
• W2108991533 hasBestOaLocation W21089915332 @default.
• W2108991533 hasConcept C126322002 @default.
• W2108991533 hasConcept C127413603 @default.
• W2108991533 hasConcept C164705383 @default.
• W2108991533 hasConcept C168563851 @default.
• W2108991533 hasConcept C197934379 @default.
• W2108991533 hasConcept C2776301958 @default.
• W2108991533 hasConcept C2776478404 @default.
• W2108991533 hasConcept C2776704044 @default.
• W2108991533 hasConcept C2776710957 @default.
• W2108991533 hasConcept C2777292125 @default.

• next